Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma

  • Authors:
    • Yong Tan
    • Jian‑Yong Zhu
    • Bao‑An Qiu
    • Nian‑Xin Xia
    • Jing‑Han Wang
  • View Affiliations

  • Published online on: August 11, 2015     https://doi.org/10.3892/ol.2015.3589
  • Pages: 2537-2542
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hilar cholangiocarcinoma is often unresectable at the time of the initial diagnosis, and the provision of a definite palliative benefit is important in patients with unresectable hilar cholangiocarcinoma. The aim of the present study was to evaluate the safety of percutaneous biliary stenting and to analyze whether percutaneous biliary stenting combined with radiotherapy (RT) prolonged the stent patency and survival time of patients. In total, the cases of 38 patients with unresectable hilar cholangiocarcinoma that underwent percutaneous biliary stenting at the Navy General Hospital were retrospectively reviewed in the present study. Uncovered metallic stenting (UMS) combined with RT was administered to 25 patients, and UMS alone was administered to 13 patients. The records of early complications subsequent to percutaneous biliary stenting were collected, and the stent patency and survival times of patients were analyzed and compared between the two groups. The technical success rate of the procedure was 100% and the successful drainage rate was 86.8%. The overall early complication rate was 15.8% and the procedure‑associated mortality rate was 2.6%. The median stent patency was 326 days in the UMS+RT group and 196 days in the UMS group (P=0.022). The UMS+RT group (median, 367 days) demonstrated a longer survival time compared with the UMS group (median, 267 days; P=0.025). Percutaneous biliary stenting offers a safe and effective method for the palliative treatment of patients with unresectable hilar cholangiocarcinoma, and percutaneous biliary stenting combined with RT may prolong stent patency and patient survival time.
View Figures
View References

Related Articles

Journal Cover

October-2015
Volume 10 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tan Y, Zhu JY, Qiu BA, Xia NX and Wang JH: Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma. Oncol Lett 10: 2537-2542, 2015
APA
Tan, Y., Zhu, J., Qiu, B., Xia, N., & Wang, J. (2015). Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma. Oncology Letters, 10, 2537-2542. https://doi.org/10.3892/ol.2015.3589
MLA
Tan, Y., Zhu, J., Qiu, B., Xia, N., Wang, J."Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma". Oncology Letters 10.4 (2015): 2537-2542.
Chicago
Tan, Y., Zhu, J., Qiu, B., Xia, N., Wang, J."Percutaneous biliary stenting combined with radiotherapy as a treatment for unresectable hilar cholangiocarcinoma". Oncology Letters 10, no. 4 (2015): 2537-2542. https://doi.org/10.3892/ol.2015.3589